{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:41:41Z","timestamp":1770986501212,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T00:00:00Z","timestamp":1538784000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00296-018-4165-3","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T02:59:48Z","timestamp":1538794788000},"page":"2157-2162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Etanercept-induced Crohn\u2019s disease in ankylosing spondylitis: a case report and review of the literature"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-3110","authenticated-orcid":false,"given":"Sena","family":"Tolu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-3854","authenticated-orcid":false,"given":"Aylin","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-2351","authenticated-orcid":false,"given":"Nurbanu","family":"Hindioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7338-6114","authenticated-orcid":false,"given":"Merve","family":"Calkin Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,6]]},"reference":[{"issue":"4","key":"4165_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","volume":"104","author":"RM Locksley","year":"2001","unstructured":"Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104(4):487\u2013501","journal-title":"Cell"},{"key":"4165_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","volume":"8","author":"P Li","year":"2017","unstructured":"Li P, Zheng Y, Chen X (2017) Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 8:460. \n                    https:\/\/doi.org\/10.3389\/fphar.2017.00460","journal-title":"Front Pharmacol"},{"issue":"2","key":"4165_CR3","doi-asserted-by":"publisher","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","volume":"2","author":"\u00c9 Toussirot","year":"2016","unstructured":"Toussirot \u00c9, Aubin F (2016) Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2(2):e000239. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2015-000239","journal-title":"RMD Open"},{"issue":"4","key":"4165_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, Davis J, van der Heide D, Haibel H, Rudwaleit M, Sieper J (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639\u2013647","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4165_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.semarthrit.2008.06.004","volume":"39","author":"B Haraoui","year":"2009","unstructured":"Haraoui B, Krelenbaum M (2009) Emergence of Crohn\u2019s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 39(3):176\u2013181. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2008.06.004\n                    \n                   (Epub 2008 Aug 15)","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"4165_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","volume":"48","author":"D Fouache","year":"2009","unstructured":"Fouache D, Go\u00ebb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M et al (2009) Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology 48(7):761\u2013764. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kep083\n                    \n                   (Epub 2009 Apr 24)","journal-title":"Rheumatology"},{"issue":"9","key":"4165_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1463-1318.2008.01490.x","volume":"10","author":"V Yazisiz","year":"2008","unstructured":"Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzio\u011flu E (2008) Development of Crohn\u2019s disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 10(9):953\u2013954. \n                    https:\/\/doi.org\/10.1111\/j.1463-1318.2008.01490.x\n                    \n                   (Epub 2008 Feb 21)","journal-title":"Colorectal Dis"},{"key":"4165_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1874312900802010053","volume":"2","author":"O Elkayam","year":"2008","unstructured":"Elkayam O, Litinsky I, Levartovsky D, Caspi D (2008) The changing face of spondyloarthropathies under TNF \u03b1 blockade. Open Rheumatol J 2:53\u201357. \n                    https:\/\/doi.org\/10.2174\/1874312900802010053\n                    \n                   (Epub 2008 Nov 14)","journal-title":"Open Rheumatol J"},{"key":"4165_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-009166","author":"H Jethwa","year":"2013","unstructured":"Jethwa H, Mann S (2013) Crohn\u2019s disease unmasked following etanercept treatment for ankylosing spondylitis. BMJ Case Rep. \n                    https:\/\/doi.org\/10.1136\/bcr-2013-009166","journal-title":"BMJ Case Rep"},{"issue":"3","key":"4165_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","volume":"44","author":"J Brandt","year":"2005","unstructured":"Brandt J, Listing J, Haibel H, S\u00f6rensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44(3):342\u2013348 (Epub 2004 Nov 23)","journal-title":"Rheumatology"},{"issue":"11","key":"4165_CR11","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 48(11):3230\u20133236","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4165_CR12","first-page":"532","volume":"35","author":"IH Song","year":"2008","unstructured":"Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, Rudwaleit M (2008) New onset of Crohn\u2019s disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 35(3):532\u2013536 (Epub 2008 Jan 15)","journal-title":"J Rheumatol"},{"issue":"12","key":"4165_CR13","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594\u20131600 (Epub 2004 Sep 2)","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4165_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/art.21588","volume":"53","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Brandt J, Listing J, Haibel H, S\u00f6rensen H, Rudwaleit M et al (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53(6):856\u2013863","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4165_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","volume":"79","author":"\u00c9 Toussirot","year":"2012","unstructured":"Toussirot \u00c9, Houvenagel \u00c9, Go\u00ebb V, Fouache D, Martin A, Le Dantec P et al (2012) Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series. Jt Bone Spine 79(5):457\u2013463. \n                    https:\/\/doi.org\/10.1016\/j.jbspin.2011.10.001\n                    \n                   (Epub 2011 Nov 15)","journal-title":"Jt Bone Spine"},{"issue":"6","key":"4165_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1080\/00365520601106228","volume":"42","author":"E Tsochatzis","year":"2007","unstructured":"Tsochatzis E, Vassilopoulos D, Manesis EK, Papatheodoridis G, Bousiotou A, Hadziyannis E, Archimandritis AJ (2007) First appearance of Crohn\u2019s disease following infliximab treatment for spondylarthropathy. Scand J Gastroenterol 42(6):784\u2013785","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"4165_CR17","first-page":"619","volume":"67","author":"D Mrabet","year":"2012","unstructured":"Mrabet D, Selmi A, Filali A, Sahli H, Sellami S (2012) Onset of Crohn\u2019s disease induced by etanercept therapy: a case report. Rev Med Liege 67(12):619\u2013622","journal-title":"Rev Med Liege"},{"issue":"6","key":"4165_CR18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","volume":"61","author":"A O\u2019Toole","year":"2016","unstructured":"O\u2019Toole A, Lucci M, Korzenik J (2016) Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA. Dig Dis Sci 61(6):1772\u20131774 \n                    https:\/\/doi.org\/10.1007\/s10620-015-4007-z\n                    \n                   (Epub 2016 Jan 4)","journal-title":"Dig Dis Sci"},{"key":"4165_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2147\/PPA.S33109","volume":"7","author":"JM Senabre-Gallego","year":"2013","unstructured":"Senabre-Gallego JM, Santos-Ram\u00edrez C, Santos-Soler G, Salas-Heredia E, S\u00e1nchez-Barrioluengo M, Barber X, Rosas J, AIRE-MB group (2013) Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence 23 7:961\u2013972. \n                    https:\/\/doi.org\/10.2147\/PPA.S33109","journal-title":"Patient Prefer Adherence 23"},{"issue":"11","key":"4165_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","volume":"16","author":"M P\u00e9rez-De-Lis","year":"2017","unstructured":"P\u00e9rez-De-Lis M, Retamozo S, Flores-Ch\u00e1vez A, Kostov B, Perez-Alvarez R, Brito-Zer\u00f3n P, Ramos-Casals M (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 16(11):1255\u20131271. \n                    https:\/\/doi.org\/10.1080\/14740338.2017.1372421\n                    \n                   (Epub 2017 Sep 7)","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"4165_CR21","first-page":"342","volume":"19","author":"KA Oikonomou","year":"2010","unstructured":"Oikonomou KA, Kapsoritakis AN, Tsiopoulos FD, Tsikouras AN, Potamianos S (2010) Emergence of Crohn\u2019s disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence? J Gastrointestin Liver Dis 19(3):342","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"4165_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.gastrohep.2016.01.011","volume":"40","author":"A Iriarte","year":"2017","unstructured":"Iriarte A, Zaera C, Bachiller-Corral J, L\u00f3pez-Sanrom\u00e1n A (2017) Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. Gastroenterol Hepatol 40(2):117\u2013121. \n                    https:\/\/doi.org\/10.1016\/j.gastrohep.2016.01.011\n                    \n                   (Epub 2016 Mar 15)","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"4165_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","volume":"20","author":"M Rudwaleit","year":"2006","unstructured":"Rudwaleit M, Baeten D (2006) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 20(3):451\u2013471","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"4165_CR24","doi-asserted-by":"publisher","first-page":"e021082","DOI":"10.1136\/bmjopen-2017-021082","volume":"8","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Bohl-B\u00fchler M, Thomas MH (2018) Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open 14 8(6):e021082. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2017-021082","journal-title":"BMJ Open 14"},{"issue":"7","key":"4165_CR25","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T (2010) Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49(7):1215\u20131228. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keq031\n                    \n                   (Epub 2010 Mar 1)","journal-title":"Rheumatology (Oxford)"},{"issue":"5 Suppl1","key":"4165_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semarthrit.2005.01.006","volume":"34","author":"J Sieper","year":"2005","unstructured":"Sieper J, Van Den Brande J (2005) Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 34(5 Suppl1):23\u201327","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"4165_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/ard.62.6.561","volume":"62","author":"J Zou","year":"2003","unstructured":"Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J (2003) Up regulation of the production of tumor necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 62(6):561\u2013564","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4165_CR28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/adc.2003.041046","volume":"89","author":"RK Russell","year":"2004","unstructured":"Russell RK, Wilson DC, Satsangi J (2004) Unravelling the complex genetics of inflammatory bowel disease. Arch Dis Child 89(7):598\u2013603","journal-title":"Arch Dis Child"},{"issue":"2","key":"4165_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239\u2013245","journal-title":"Clin Pharmacol Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4165-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T19:22:20Z","timestamp":1570303340000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4165-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,6]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4165"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4165-3","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,6]]},"assertion":[{"value":"11 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflict of interest was declared by the authors. All authors had no relationships to any pharma agencies within the past 36\u00a0months.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient consented to publication of his case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}